REMETRY Trademark

Trademark Overview

On Thursday, April 6, 2006, a trademark application was filed for REMETRY with the United States Patent and Trademark Office. The USPTO has given the REMETRY trademark a serial number of 78855231. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, September 28, 2009. This trademark is owned by PDL Biopharma, Inc.. The REMETRY trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Scientific and medical research in the fields of development and testing of drugs for cardiac diseases and renal disorders; scientific and medical research in the fields of prevention, diagnosis and treatment of cardiac diseases and renal disorders
remetry

General Information

Serial Number78855231
Word MarkREMETRY
Filing DateThursday, April 6, 2006
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, September 28, 2009
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 5, 2006

Trademark Statements

Goods and ServicesScientific and medical research in the fields of development and testing of drugs for cardiac diseases and renal disorders; scientific and medical research in the fields of prevention, diagnosis and treatment of cardiac diseases and renal disorders

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, April 11, 2006
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameEKR THERAPEUTICS, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressBEDMINSTER, NJ 07921
Party NamePDL Biopharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRedwood City, CA 94063
Party NamePDL Biopharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressFremont, CA 94555

Trademark Events

Event DateEvent Description
Monday, September 28, 2009ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, September 28, 2009ABANDONMENT - NO USE STATEMENT FILED
Thursday, March 12, 2009EXTENSION 4 GRANTED
Wednesday, February 25, 2009EXTENSION 4 FILED
Thursday, March 12, 2009CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, February 25, 2009TEAS EXTENSION RECEIVED
Tuesday, August 26, 2008EXTENSION 3 GRANTED
Tuesday, August 26, 2008EXTENSION 3 FILED
Tuesday, August 26, 2008TEAS EXTENSION RECEIVED
Wednesday, July 30, 2008AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, July 2, 2008ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, July 2, 2008TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, February 11, 2008EXTENSION 2 GRANTED
Monday, February 11, 2008EXTENSION 2 FILED
Monday, February 11, 2008TEAS EXTENSION RECEIVED
Thursday, October 18, 2007APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, October 18, 2007TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, October 18, 2007TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, September 21, 2007EXTENSION 1 GRANTED
Friday, August 17, 2007EXTENSION 1 FILED
Friday, August 17, 2007TEAS EXTENSION RECEIVED
Tuesday, February 27, 2007NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 5, 2006PUBLISHED FOR OPPOSITION
Wednesday, November 15, 2006NOTICE OF PUBLICATION
Tuesday, October 17, 2006LAW OFFICE PUBLICATION REVIEW COMPLETED
Monday, October 16, 2006ASSIGNED TO LIE
Monday, October 2, 2006ASSIGNED TO LIE
Monday, September 25, 2006APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, September 18, 2006ASSIGNED TO EXAMINER
Tuesday, April 11, 2006NEW APPLICATION ENTERED IN TRAM

Related Keywords

remetry renal scientific cardiac disorders fields medical research diseases diagnosis treatment